Biotech Values

[genisi]

Perhaps because ApoE4 genotype prevalence among AD patients in north EU and USA is around 60% and they hope that if they start the anti-Aß therapy early - before the ß-amyloid plaque burden is too heavy, it might improve the patient's state.